UAS™—A Urine Preservative for Oncology Applications-Reference-Cited by-同舟云学术

UAS™—A Urine Preservative for Oncology Applications

Published:2023-06-08 Issue:12 Volume:15 Page:3119
ISSN:2072-6694
Container-title:Cancers
language:en
Short-container-title:Cancers

Author:

Jordaens Stephanie¹²^ORCID,Arora Amit³,MacDonald Kyle W.³,Wood Cameron³,Hendrickx Jhana O.²^ORCID,Zwaenepoel Karen¹⁴^ORCID,Deben Christophe¹^ORCID,Tjalma Wiebren¹⁵,Pauwels Patrick¹⁴,Beyers Koen²^ORCID,Vankerckhoven Vanessa²⁶^ORCID

Affiliation:

1. Center for Oncological Research (CORE), Integrated Personalized & Precision Oncology Network (IPPON), University of Antwerp, 2610 Wilrijk, Belgium

2. Novosanis NV, 2110 Wijnegem, Belgium

3. DNA Genotek Inc., Ottawa, ON K2V 1C2, Canada

4. Laboratory of Pathological Anatomy, Antwerp University Hospital (UZA), 2650 Edegem, Belgium

5. Multidisciplinary Breast Clinic, Gynecological Oncology Unit, Department of Obstetrics and Gynecology, Antwerp University Hospital (UZA), 2650 Edegem, Belgium

6. Vaccine & Infectious Disease Institute (VAXINFECTIO), Faculty of Medicine and Health Sciences, University of Antwerp, 2610 Wilrijk, Belgium

Abstract

Liquid biopsy is a revolutionary tool that is gaining momentum in the field of cancer research. As a body fluid, urine can be used in non-invasive diagnostics for various types of cancer. We investigated the performance of UAS™ as a preservative for urinary analytes. Firstly, the need for urine preservation was investigated using urine samples from healthy volunteers. Secondly, the performance of UAS™ was assessed for cell-free DNA (cfDNA) and host cell integrity during storage at room temperature (RT) and after freeze-thaw cycling. Finally, UAS™ was used in a clinical setting on samples from breast and prostate cancer patients. In the absence of a preservative, urinary cfDNA was degraded, and bacterial overgrowth occurred at RT. In urine samples stored in UAS™, no microbial growth was seen, and cfDNA and cellular integrity were maintained for up to 14 days at RT. After freeze-thaw cycling, the preservation of host cell integrity and cfDNA showed significant improvements when using UAS™ compared to unpreserved urine samples. Additionally, UAS™ was found to be compatible with several commercially available isolation methods.

Funder

Flemish Agency for Innovation and Entrepreneurship—VLAIO

Publisher

MDPI AG

Subject

Cancer Research,Oncology

Link

https://www.mdpi.com/2072-6694/15/12/3119/pdf

Reference31 articles.

1. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries;Sung;CA Cancer J. Clin.,2021

2. Tsui, N.B., Jiang, P., Chow, K.C., Su, X., Leung, T.Y., Sun, H., Chan, K.C., Chiu, R.W., and Lo, Y.M. (2012). High resolution size analysis of fetal DNA in the urine of pregnant women by paired-end massively parallel sequencing. PLoS ONE, 7.

3. Liquid biopsy: A step forward towards precision medicine in urologic malignancies;Bartlett;Mol. Cancer,2017

4. Larsen, L.K., Lind, G.E., Guldberg, P., and Dahl, C. (2019). DNA-Methylation-Based Detection of Urological Cancer in Urine: Overview of Biomarkers and Considerations on Biomarker Design, Source of DNA, and Detection Technologies. Int. J. Mol. Sci., 20.

5. Kretschmer-Kazemi Far, R., Frank, K., and Sczakiel, G. (2021). Sampling, Logistics, and Analytics of Urine for RT-qPCR-based Diagnostics. Cancers, 13.